Karl Kölbeck

2.7k total citations · 1 hit paper
23 papers, 736 citations indexed

About

Karl Kölbeck is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Karl Kölbeck has authored 23 papers receiving a total of 736 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Pulmonary and Respiratory Medicine, 10 papers in Oncology and 5 papers in Molecular Biology. Recurrent topics in Karl Kölbeck's work include Lung Cancer Treatments and Mutations (12 papers), Lung Cancer Diagnosis and Treatment (6 papers) and Lung Cancer Research Studies (4 papers). Karl Kölbeck is often cited by papers focused on Lung Cancer Treatments and Mutations (12 papers), Lung Cancer Diagnosis and Treatment (6 papers) and Lung Cancer Research Studies (4 papers). Karl Kölbeck collaborates with scholars based in Sweden, United Kingdom and United States. Karl Kölbeck's co-authors include Tony Mok, Shun Lü, Michael Boyer, Janessa Laskin, Kenneth J. O’Byrne, Vera Hirsh, Luis Paz‐Ares, Angela Märten, James Chih‐Hsin Yang and Gunnar Hillerdal and has published in prestigious journals such as Journal of Clinical Oncology, Scientific Reports and Annals of Oncology.

In The Last Decade

Karl Kölbeck

22 papers receiving 720 citations

Hit Papers

Afatinib versus gefitinib... 2017 2026 2020 2023 2017 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial
    2017 398 citations Luis Paz‐Ares, E.H. Tan et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Karl Kölbeck Sweden 11 598 483 155 97 50 23 736
Naoki Furuya Japan 16 590 1.0× 510 1.1× 181 1.2× 126 1.3× 27 0.5× 89 827
D. H. Lee South Korea 12 670 1.1× 537 1.1× 164 1.1× 120 1.2× 50 1.0× 15 880
Xiaobo He China 7 215 0.4× 412 0.9× 79 0.5× 166 1.7× 22 0.4× 8 561
Carina Hillenbach Switzerland 7 319 0.5× 383 0.8× 111 0.7× 65 0.7× 99 2.0× 11 630
Sakiko Otani Japan 13 404 0.7× 465 1.0× 142 0.9× 92 0.9× 15 0.3× 45 613
Marta Batus United States 13 243 0.4× 296 0.6× 178 1.1× 83 0.9× 51 1.0× 60 569
J. Michel Belgium 15 504 0.8× 662 1.4× 217 1.4× 66 0.7× 57 1.1× 24 903
Seisuke Nagase Japan 11 681 1.1× 607 1.3× 174 1.1× 104 1.1× 45 0.9× 18 841
Aurelio Castrellon United States 12 392 0.7× 429 0.9× 102 0.7× 210 2.2× 18 0.4× 34 655
Ou Yamaguchi Japan 19 677 1.1× 910 1.9× 132 0.9× 86 0.9× 78 1.6× 88 1.1k

Countries citing papers authored by Karl Kölbeck

Since Specialization
Citations

This map shows the geographic impact of Karl Kölbeck's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karl Kölbeck with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karl Kölbeck more than expected).

Fields of papers citing papers by Karl Kölbeck

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Karl Kölbeck. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karl Kölbeck. The network helps show where Karl Kölbeck may publish in the future.

Co-authorship network of co-authors of Karl Kölbeck

This figure shows the co-authorship network connecting the top 25 collaborators of Karl Kölbeck. A scholar is included among the top collaborators of Karl Kölbeck based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karl Kölbeck. Karl Kölbeck is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Levitsky, Adrian, Britt‐Marie Bernhardson, Ingela Henoch, et al.. (2021). Using patients’ own knowledge of early sensations and symptoms to develop an interactive, individualized e-questionnaire to facilitate early diagnosis of lung cancer. BMC Cancer. 21(1). 544–544. 2 indexed citations
3.
Levitsky, Adrian, Maria Pernemalm, Britt‐Marie Bernhardson, et al.. (2019). Early symptoms and sensations as predictors of lung cancer: a machine learning multivariate model. Scientific Reports. 9(1). 16504–16504. 19 indexed citations
4.
Schüler, Martin, Eng-Huat Tan, Kenneth J. O’Byrne, et al.. (2019). First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression. Journal of Cancer Research and Clinical Oncology. 145(6). 1569–1579. 31 indexed citations
5.
Kölbeck, Karl, et al.. (2018). Optimizing diffusion-weighted magnetic resonance imaging for evaluation of lung tumors: A comparison of respiratory triggered and free breathing techniques. European Journal of Radiology Open. 5. 189–193. 6 indexed citations
6.
Park, K., E.H. Tan, L. Zhang, et al.. (2017). Afatinib vs gefitinib in patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC: overall survival (OS) data from LUX-Lung 7 (LL7). European Journal of Cancer. 72. S184–S184. 1 indexed citations
7.
Paz‐Ares, Luis, E.H. Tan, Kenneth J. O’Byrne, et al.. (2017). Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial. Annals of Oncology. 28(2). 270–277. 398 indexed citations breakdown →
8.
Park, Keunchil, Eng Huat Tan, Li Zhang, et al.. (2017). OA23.05 First-Line Afatinib versus Gefitinib in EGFRm+ Advanced NSCLC: Updated Overall Survival Analysis of LUX-Lung 7. Journal of Thoracic Oncology. 12(1). S335–S336. 1 indexed citations
9.
Murgia, Nicola, et al.. (2017). Mutational status predicts the risk of thromboembolic events in lung adenocarcinoma. Multidisciplinary Respiratory Medicine. 12(1). 16–16. 22 indexed citations
10.
11.
12.
13.
Hirsh, Vera, James Chih‐Hsin Yang, Kenneth J. O’Byrne, et al.. (2016). First-line afatinib (A) vs gefitinib (G) for patients (pts) with EGFR mutation positive (EGFRm+) NSCLC (LUX-Lung 7): Patient-reported outcomes (PROs) and impact of dose modifications on efficacy and adverse events (AEs).. Journal of Clinical Oncology. 34(15_suppl). 9046–9046. 11 indexed citations
14.
Hillerdal, Gunnar, Karl Kölbeck, & Hans Jacobsson. (2013). [Pulmonary tularemia: rare disease that can be interpreted as lung cancer. Serology provides the correct diagnosis, as shown by case reports].. PubMed. 110(27-28). 1280–1. 2 indexed citations
15.
Kearley, Jennifer, Jonas S. Erjefält, Cecilia Andersson, et al.. (2009). A Central Role for IL-9 in Mediating Mast Cell Progenitor Mobilization to the Lung and Chronic Remodeling of the Airways.. A3707–A3707. 1 indexed citations
16.
Sederholm, Christer, Gunnar Hillerdal, Kristina Lamberg, et al.. (2005). Phase III Trial of Gemcitabine Plus Carboplatin Versus Single-Agent Gemcitabine in the Treatment of Locally Advanced or Metastatic Non–Small-Cell Lung Cancer: The Swedish Lung Cancer Study Group. Journal of Clinical Oncology. 23(33). 8380–8388. 146 indexed citations
17.
18.
Tornhamre, Susanne, et al.. (2002). Uncoupled regulation of leukotriene C4 synthase in platelets from aspirin‐intolerant asthmatics and healthy volunteers after aspirin treatment. Clinical & Experimental Allergy. 32(11). 1566–1573. 18 indexed citations
19.
Kölbeck, Karl, et al.. (2000). Airway reactivity and exhaled NO following swine dust exposure in healthy volunteers. Respiratory Medicine. 94(11). 1065–1072. 21 indexed citations
20.
Hallén, Hans, P. Gräf, Karl Kölbeck, & J.-E. Juto. (1995). Airway Reactivity of Nose and Bronchi in Patients with Nasal. ORL. 57(6). 328–332. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Naoki Furuya Breakdown of academic impact, for papers by D. H. Lee Breakdown of academic impact, for papers by Xiaobo He Breakdown of academic impact, for papers by Carina Hillenbach Breakdown of academic impact, for papers by Sakiko Otani Breakdown of academic impact, for papers by Marta Batus Breakdown of academic impact, for papers by J. Michel Breakdown of academic impact, for papers by Seisuke Nagase Breakdown of academic impact, for papers by Aurelio Castrellon Breakdown of academic impact, for papers by Ou Yamaguchi
Rankless by CCL
2026